See more : UIL Finance Limited (UTLH.L) Income Statement Analysis – Financial Results
Complete financial analysis of Applied Genetic Technologies Corporation (AGTC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Applied Genetic Technologies Corporation, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Summit Hotel Properties, Inc. (INN-PF) Income Statement Analysis – Financial Results
- Komplett Bank ASA (0EFW.L) Income Statement Analysis – Financial Results
- CRH plc (CRH) Income Statement Analysis – Financial Results
- Bedmutha Industries Limited (BEDMUTHA.BO) Income Statement Analysis – Financial Results
- Denkyo Group Holdings Co.,Ltd. (8144.T) Income Statement Analysis – Financial Results
Applied Genetic Technologies Corporation (AGTC)
About Applied Genetic Technologies Corporation
Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. Its advanced product candidates include three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which is in the Phase 1/2 clinical trials; and achromatopsia that is in Phase 1/2 clinical trials. It is also developing an optogenetic product candidate to treat advanced retinal disease. In addition, the company has initiated one preclinical program in otology; preclinical program in dry age-related macular degeneration; and two preclinical programs in targeting central nervous system disorders, including frontotemporal dementia and amyotrophic lateral sclerosis. It has collaboration agreements with University of Florida; Bionic Sight, Inc.; and Otonomy, Inc. The company was incorporated in 1999 and is headquartered in Alachua, Florida.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 325.00K | 500.00K | 2.45M | 41.69M | 24.19M | 39.47M | 47.36M | 2.35M | 1.13M | 942.00K | 1.08M |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 325.00K | 500.00K | 2.45M | 41.69M | 24.19M | 39.47M | 47.36M | 2.35M | 1.13M | 942.00K | 1.08M |
| Gross Profit Ratio | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 49.52M | 44.40M | 35.78M | 33.18M | 32.18M | 26.22M | 38.86M | 16.53M | 8.50M | 3.13M | 2.35M |
| General & Administrative | 16.99M | 14.55M | 13.62M | 12.86M | 14.39M | 11.35M | 10.59M | 10.36M | 5.18M | 1.40M | 787.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 16.99M | 14.55M | 13.62M | 12.86M | 14.39M | 11.35M | 10.59M | 10.36M | 5.18M | 1.40M | 787.00K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 66.50M | 58.95M | 49.40M | 46.04M | 46.57M | 37.57M | 49.45M | 26.89M | 13.69M | 4.54M | 3.14M |
| Cost & Expenses | 66.50M | 58.95M | 49.40M | 46.04M | 46.57M | 37.57M | 49.45M | 26.89M | 13.69M | 4.54M | 3.14M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 42.00K | 0.00 | 0.00 |
| Interest Expense | 2.67M | 1.51M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 191.00K | 69.00K |
| Depreciation & Amortization | 1.51M | 1.46M | 1.34M | 1.27M | 1.18M | 912.00K | 567.00K | 376.00K | 334.00K | 285.00K | 262.00K |
| EBITDA | -64.76M | -56.97M | -46.94M | -4.35M | -20.05M | 3.72M | -814.00K | -24.53M | -12.56M | -4.51M | -1.59M |
| EBITDA Ratio | -19,925.23% | -11,394.20% | -1,813.05% | -1.58% | -82.91% | 9.42% | -1.72% | -1,017.08% | -1,379.45% | -479.19% | -147.23% |
| Operating Income | -66.27M | -58.45M | -46.94M | -4.35M | -22.38M | 1.90M | -2.09M | -24.53M | -12.56M | -3.59M | -2.06M |
| Operating Income Ratio | -20,390.46% | -11,690.20% | -1,913.66% | -10.43% | -92.55% | 4.82% | -4.41% | -1,042.14% | -1,112.13% | -381.53% | -190.30% |
| Total Other Income/Expenses | -2.58M | -1.39M | 1.18M | 2.46M | 1.18M | 905.00K | 708.00K | 214.00K | -3.35M | -1.40M | 135.00K |
| Income Before Tax | -68.75M | -59.84M | -45.76M | -1.90M | -21.21M | 2.81M | -1.38M | -24.32M | -15.91M | -4.99M | -1.92M |
| Income Before Tax Ratio | -21,153.85% | -11,968.20% | -1,865.55% | -4.55% | -87.69% | 7.11% | -2.92% | -1,033.05% | -1,409.03% | -529.72% | -177.82% |
| Income Tax Expense | 2.67M | -2.11M | 83.00K | 76.00K | 72.00K | 2.40M | 708.00K | 214.00K | -3.35M | -1.21M | 204.00K |
| Net Income | -71.42M | -57.83M | -45.89M | -2.01M | -21.30M | 407.00K | -1.38M | -24.32M | -15.91M | -4.99M | -1.92M |
| Net Income Ratio | -21,976.62% | -11,565.80% | -1,870.85% | -4.81% | -88.07% | 1.03% | -2.92% | -1,033.05% | -1,409.03% | -529.72% | -177.82% |
| EPS | -1.59 | -1.77 | -2.17 | -0.11 | -1.18 | 0.02 | -0.08 | -1.50 | -4.46 | -1.20 | -0.28 |
| EPS Diluted | -1.59 | -1.77 | -2.17 | -0.11 | -1.18 | 0.02 | -0.08 | -1.50 | -4.46 | -1.20 | -0.28 |
| Weighted Avg Shares Out | 45.03M | 32.76M | 21.10M | 18.16M | 18.11M | 18.07M | 17.81M | 16.25M | 3.57M | 4.15M | 6.89M |
| Weighted Avg Shares Out (Dil) | 45.03M | 32.76M | 21.10M | 18.16M | 18.11M | 18.39M | 17.81M | 16.25M | 3.57M | 4.15M | 6.89M |
AGTC to Present at the OIS Gene Therapy Innovation Showcase on February 18, 2021
GAINESVILLE, Fla. and CAMBRIDGE, Mass., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that Sue...
AGTC to Present at the 4th Annual Gene Therapy for Rare Disorders Digital Event, February 22-25, 2021
-AGTC executives will address critical success factors in gene therapy manufacturing and the value of the patient perspective in gene therapy development ---- GAINESVILLE, Fla. and CAMBRIDGE, Mass., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC),...
Applied Genetic Technologies Corporation (AGTC) CEO Sue Washer on Q2 2021 Results - Earnings Call Transcript
Applied Genetic Technologies Corporation (AGTC) CEO Sue Washer on Q2 2021 Results - Earnings Call Transcript
AGTC Announces Financial Results and Business Update for the Quarter Ended December 31, 2020
- Company on track to provide multiple data readouts for XLRP and ACHM clinical programs in 2021 and 2022 -
AGTC Executives Awarded First Place in the BioProcess International Reader's Choice Awards, Cell & Gene Therapies Category
Article reflects Company's leadership and innovation in scalable, reproducible manufacture of adeno-associated virus (AAV)-based gene therapies
AGTC to Host Second Quarter Financial Results Conference Call and Webcast on February 11, 2021
GAINESVILLE, Fla. and CAMBRIDGE, Mass., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that it...
AGTC Announces Pricing of Public Offering of Common Stock and Warrants
GAINESVILLE, Fla., and CAMBRIDGE, Mass., Jan. 28, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced the pricing...
AGTC Announces Proposed Public Offering of Common Stock and Warrants
GAINESVILLE, Fla., and CAMBRIDGE, Mass., Jan. 27, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that it...
AGTC Announces First Reported Improvements in Visual Sensitivity for Achromatopsia (ACHM) patients from its Ongoing Clinical Trials
-Preliminary results suggest sustained improvements to 12-months in visual sensitivity, as measured by full field static perimetry, supported in some patients by other endpoints- -Company plans longer term follow-up, dosing of younger pediatric patients, and addition of new brain imaging...
AGTC to Participate in the H.C. Wainwright BioConnect 2021 Conference
GAINESVILLE, Fla. and CAMBRIDGE, Mass., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company focused on developing adeno-associated virus (AAV) based gene therapies for the treatment of rare inherited diseases, today announced that Sue...
Source: https://incomestatements.info
Category: Stock Reports